Abstract

BackgroundTo facilitate new drug development, physiologically-based pharmacokinetic (PBPK) modeling methods receive growing attention as a tool to fully understand and predict complex pharmacokinetic phenomena. As the number of parameters to reproduce physiological functions tend to be large in PBPK models, efficient parameter estimation methods are essential. We have successfully applied a recently developed algorithm to estimate a feasible solution space, called Cluster Newton Method (CNM), to reveal the cause of irinotecan pharmacokinetic alterations in two cancer patient groups.ResultsAfter improvements in the original CNM algorithm to maintain parameter diversities, a feasible solution space was successfully estimated for 55 or 56 parameters in the irinotecan PBPK model, within ten iterations, 3000 virtual samples, and in 15 minutes (Intel Xeon E5-1620 3.60GHz × 1 or Intel Core i7-870 2.93GHz × 1). Control parameters or parameter correlations were clarified after the parameter estimation processes. Possible causes in the irinotecan pharmacokinetic alterations were suggested, but they were not conclusive.ConclusionsApplication of CNM achieved a feasible solution space by solving inverse problems of a system containing ordinary differential equations (ODEs). This method may give us reliable insights into other complicated phenomena, which have a large number of parameters to estimate, under limited information. It is also helpful to design prospective studies for further investigation of phenomena of interest.

Highlights

  • To facilitate new drug development, physiologically-based pharmacokinetic (PBPK) modeling methods receive growing attention as a tool to fully understand and predict complex pharmacokinetic phenomena

  • Improvements in Cluster Newton Method (CNM) for analyzing irinotecan accumulation profiles In this study, we have applied and improved the CNM algorithm for the accumulation profiles of irinotecan and its metabolites by using the PBPK model shown in Figure 1 and in Additional File 1

  • We examined the effect of dS values on the convergence in this system, which was newly introduced in the algorithm to maintain parameter diversities as explained in the Methods section, and the calculation with dS of 0 is identical to the original CNM algorithm

Read more

Summary

Introduction

To facilitate new drug development, physiologically-based pharmacokinetic (PBPK) modeling methods receive growing attention as a tool to fully understand and predict complex pharmacokinetic phenomena. A major purpose of this study area is to predict pharmacokinetic properties of new drugs in humans, without performing clinical studies, in order to accelerate the efficiencies of new drug development processes. Another important purpose is to facilitate the proper use of newly. Physiologically-based pharmacokinetic (PBPK) modeling and simulation are essential in understanding and predicting the above-mentioned, complicated pharmacokinetic phenomena [6,7,8]. Current draft guidance on DDI studies by the U.S Food and Drug Administration [11] emphasizes the importance of PBPK simulation in deciding whether clinical DDI studies are required or not during new drug developments

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call